

Photo Album

by dc







NOVAMIND

Disclaimer

This presentation (the "Presentation") of Novamind Ventures Inc. (the "Company") is current as of October 1, 2020, except as otherwise provided herein. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. An investment in the Company is speculative and involves substantial risk and is only suitable for investors that are able to bear the risk of losing their entire investment. All of the information contained in this Presentation is for preliminary discussion purposes only. Final terms and conditions may change without notice and are subject to further discussion and negotiations.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. Persons receiving or reviewing this Presentation should not rely upon it as a complete overview of the business of the Company and should rely on their own investigation and due diligence. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The contents of this Presentation are not to be construed as legal, financial or tax advice. You should consult your tax or legal advisor about the information contained in this Presentation.

Certain statements in this Presentation may constitute forward-looking information within the meaning of applicable securities laws. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "expects," "believes," "anticipates," "budget," "scheduled," "estimates," "forecasts," "intends," "plans," and variations of such words and phrases, or by statements that certain actions, events or results "may," "will," "could," "would," or "might," "be taken," "occur," or "be achieved." Certain statements, beliefs and opinions in this Presentation (including those contained in graphs, tables and charts), which reflect the Company's or, as appropriate, the Company's managements' current expectations and projections about future events, constitute forward-looking information. Forward-looking information contained in this Presentation is based on certain assumptions regarding, among other things, expected growth, results of operations, performance, industry trends and growth opportunities. Forward-looking information contained in this Presentation includes, statements in respect of expected developments in the legal framework for psychedelics by the legal and regulatory authorities in Canada, anticipated revenue projections, and the expansion of businesses of the Company's subsidiaries, Cedar Clinical Research, Inc. and Cedar Psychiatry, Inc. (the "Subsidiaries"). While revenue projections and proposed expansion are based on management's business plans, assumptions related to the legal framework of psychedelics are based on management's observation of general trends in society relating to the acceptance of psychedelics in therapeutic treatments, making them harder to quantify and predict than those matters that management may have control or involvement in. While management considers these assumptions to be reasonable, based on information available on the date hereof, they may prove to be incorrect.

Disclaimer continued

By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and other factors include: (i) the ability of individuals to access the Company's services through third-party payors; (ii) future legislative and regulatory developments including with respect to the legal treatment of psychedelics; (iii) the Company's ability to implement and fulfill its business strategies (including expansion of the business of the Subsidiaries) in accordance with its business plan; (iv) the willingness and ability of patients to enrol in the Company's programs; (v) the availability of financing and the potential inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; (vi) the Company's ability to retain professionals, including appropriately trained medical personnel, to provide services in connection with its business; (vii) force majeure events; (viii) general economic conditions; (ix) adverse industry events; (x) marketing costs; (xi) loss of potential markets; (xiii) tax and regulatory matters; and (xiv) competition. The foregoing factors are not intended to be exhaustive. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this Presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

In this Presentation, and during the course of discussions related to the evaluation of any prospective investment in the Company (the "Purpose"), the Company may disclose certain information which it deems proprietary or confidential, and may include, discoveries, ideas, concepts, know-how, techniques, designs, specifications, drawings, blueprints, diagrams, flow charts, data, costs, prices, marketing plans, goals, sales figures, revenue, profits, and other technical, financial or business information respecting existing or planned product or service offerings, including products and services to be developed or marketed by the Company (the "Information"). At all times, Information shall be deemed confidential and proprietary and subject to the restricted use of evaluating the business of the Company for the Purpose and distribution shall be prohibited, other than as provided herein.

This Presentation includes financial outlook about the Company's projected revenue, which is subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. Revenue estimates contained in this Presentation were made by management and are provided for the purpose of providing readers with an understanding of management's expectations with respect to the potential financial performance of the Company, assuming that certain business objectives and milestones are met. Readers are cautioned that the financial outlook contained in this document should not be used for purposes other than for which it is disclosed herein.

By your acceptance of this Presentation, if delivered, you and any person reviewing this Presentation agrees not to distribute, copy; reproduce; transmit; make available; or condone any of the foregoing, without the prior written consent of the Company. Any unauthorized use of this Presentation is strictly prohibited. No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise.

Company highlights

Operating the infrastructure required for a regulated psychedelics industry

- > Strong network of outpatient mental health clinics and clinical research sites
- > Rapid expansion of clinics and research sites
- > Specialized in psychedelic-assisted treatment protocols
- > Building centers of excellence for future approved psychedelic treatments



Our focus



Clinical care

Ketamine-assisted psychotherapy
+ other innovative therapies




Research

Clinical research for
psychedelic medicines



Retreat network

Legal, medically supervised
psychedelic experiences



Global access to psychedelic medicines

- > Novamind is growing a network of specialized psychedelic clinics and retreats
- > Treatment is provided by blending evidence-based principles with psychedelic medicines
- > We guide individuals through their entire healing journey, both at home and abroad



A brief history of psychedelics

Pre-1900

First wave

INDIGENOUS USE

The ritual use of psychedelics predates recorded history



Psychedelics include:



Ayahuasca



Psilocybin mushrooms



Iboga



Peyote

1900-1990

Second wave

EARLY-MID 1900s

Pharmaceutical companies isolate compounds including:

MDMA
Psilocybin
LSD



1950-1965

40,000 patients are prescribed LSD therapy



JUNE 1971

President Nixon declared a "War on Drugs"



1970s-1985

MDMA was embraced in psychotherapy until falling victim to the War on Drugs



1990-Present

Third wave

1990s-LATE 2010s

Academic studies re-establish the therapeutic potential of psychedelics



2013-2019

The FDA grants breakthrough therapy status to esketamine, MDMA and psilocybin



CURRENT DAY

MDMA Phase III clinical trial (PTSD)

Psilocybin Phase IIB clinical trial (depression)

100's of early-stage clinical trials



A mental healthcare revolution has begun

[4 Canadians with terminal cancer win the right to try magic mushrooms ↗](#)

AUGUST 5, 2020

[We can no longer ignore the potential of psychedelic drugs to treat depression ↗](#)

JUNE 8, 2020

[FDA Agrees to Expanded Access Program for MDMA-Assisted Psychotherapy for PTSD ↗](#)

JANUARY 17, 2020



Compelling clinical data is re-establishing the use of psychedelic medicines

Drug	Indication	Evidence
Ketamine	Prescribed off-label	A single infusion of ketamine can mitigate symptoms of suicidal ideation within 1 hour ¹
Spravato™ (esketamine)	FDA approved for TRD & MDD	A single dose of esketamine can improve symptoms of depression and suicidal ideation within 2-4 hours ²
MDMA	Phase III for PTSD*	Up to 12 months post-treatment, 67% of patients did not qualify for a PTSD diagnosis ³
Psilocybin	Phase IIB for TRD*	42% of patients treated with psilocybin were in complete remission 3 months post-treatment ⁴

*Granted Breakthrough Therapy Designation from the FDA

TRD: treatment-resistant depression
 MDD: major depressive disorder
 PTSD: post-traumatic stress disorder

US\$224B

US annual spend on mental health services ⁵

US\$17B

US annual spend on depression and anxiety treatments ⁶

1: <https://www.uptodate.com/contents/ketamine-and-esketamine-for-treating-unipolar-depression-in-adults-administration-efficacy-and-adverse-effects/abstract/48.56.57>
 2: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534172/>
 3: <https://maps.org/news/media/8190-press-release-mdma-assisted-psychotherapy-may-have-lasting-benefits-for-ptsd--results-published-in-psychopharmacology>
 4: [https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366\(16\)30065-7/fulltext](https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(16)30065-7/fulltext)
 5: <https://www.openminds.com/intelligence-report/the-u-s-mental-health-market-225-1-billion-in-spending-in-2019-an-open-minds-market-intelligence-report/>
 6: <https://www.globenewswire.com/news-release/2019/05/15/1825506/0/en/Anxiety-Disorder-and-Depression-Treatment-Market-To-Reach-USD-18-90-Billion-By-2026-Reports-And-Data.html>



Full service outpatient mental health clinics specialized in ketamine-assisted psychotherapy

Cedar's offerings

- › Ketamine-assisted psychotherapy, **over 3,000 treatments** administered
- › Spravato™ therapy, **over 1,000 treatments** administered
- › Psychotherapy and medication management
- › Transcranial Magnetic Stimulation (TMS) therapy

Cedar's clinics (Utah, USA)

- › Clinics in operation: (4) Springville, Orem, Salt Lake City & Layton
- › Clinics in development: (1) Draper – anticipated by Q2 2021





A psychedelic CRO for clinical phase development

- › Cedar Clinical Research (CCR) has significant experience in hosting phase I to IV clinical trials and research studies
- › A recognized leader in clinical research focused on emerging treatment options in neuropsychiatry
 - › Led Spravato™ trials in Utah for Janssen Pharmaceuticals
 - › Dr. Robison is Coordinating Investigator of MAPS' clinical trial examining MDMA-assisted psychotherapy as a treatment for eating disorders
- › Creating a specialized network of clinical trial sites for psychedelic drug development
- › Developing innovative psychedelic treatment protocols



Novel psychedelic treatment protocols

Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP) is a treatment protocol combining emotion-focused therapy and ketamine-assisted psychotherapy, developed by Dr. Adele Lafrance and Dr. Reid Robison, Chief Medical Officer of Novamind

- › The protocol targets emotion processing and leverages family systems in the patient's healing process
- › EF-KAP is a manualized treatment protocol that enables the training of clinicians at scale
- › EF-KAP is the first of multiple novel treatment protocols in development
- › CCR is currently conducting IRB-approved studies investigating EF-KAP as a treatment for anorexia nervosa and major depressive disorder

